Title: Your patient may choose to stay home watching classic movies.
Title: Or he may go out for a walk after breakfast.
Copy:
Your patient may have more choices. You just have to share yours.
In mCRPC, Xtandi is is the treatment option that effectively blocks androgen activity with less restrictions:
- No need for fasting before or after taking the medication
- No need for corticosteroids
- Daily dosage, with the practicality and safety of the sealed blister.
Title: Your patient may choose to come home earlier to stay with the family.
Title 2: Or he may go out for a late dinner at his favorite restaurant.
Copy:
Your patient may have more choices. You just have to share yours.
In mCRPC, Xtandi is is the treatment option that effectively blocks androgen activity with less restrictions:
- No need for fasting before or after taking the medication
- No need for corticosteroids
- Daily dosage, with the practicality and safety of the sealed blister.
Title: Your patient may choose to keep studying whatever he wants.
Title 2: Or he may learn new stories to tell his grandson.
Copy:
Your patient may have more choices. You just have to share yours.
In mCRPC, Xtandi is is the treatment option that effectively blocks androgen activity with less restrictions:
- No need for fasting before or after taking the medication
- No need for corticosteroids
- Daily dosage, with the practicality and safety of the sealed blister.
Medical Visual Aid
Translation:
A change of perspective begins with your choice.
Translation:
Studies show that 90% of newly diagnosed men with prostate cancer prefer an active role in decision making.
Translation:
Studies show that sharing decisions with patients and promoting conscious choice about treatment is a worldwide trend.
- Defining the problem
- Showing the options
- Talking about pros and cons, values and patient’s personal preferences
- Discussing patient’s capabilities and medical knowledge
- Checking understandment
- Making decision or making it explicit
- Planning follow-up
Translation:
When compared to abiraterone, different studies show that using Xtandi® in the first line was associated with a better rate of:
- Overall survival and progression-free survival
- Radiographic progression-free survival
- PSA response
- PSA progression time
M. Battistella 